{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:24:40Z","timestamp":1782969880111,"version":"3.54.5"},"reference-count":24,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["#500464"],"award-info":[{"award-number":["#500464"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Many patients receive oral anticoagulation for reduced stroke risk in atrial fibrillation or as treatment or prevention of venous thromboembolism. Oral factor Xa inhibitors (oral FXaI, eg, apixaban, edoxaban or rivaroxaban) are commonly prescribed for this indication. Dabigatran, an oral direct thrombin inhibitor, is similarly approved. In vitro and animal model evidence suggests that dabigatran also has direct effects on\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      virulence and infection. Observational data have shown that dabigatran users are less likely to develop\n                      <jats:italic>S. aureus<\/jats:italic>\n                      bacteremia (SAB), and a small randomised controlled trial showed that dabigatran has anti-\n                      <jats:italic>S. aureus<\/jats:italic>\n                      effects when compared with low molecular weight heparins during bloodstream infection. We seek to answer whether dabigatran is superior to the oral FXaIs in achieving better SAB outcomes among patients who independently require oral anticoagulation. We report the intervention-specific protocol, embedded in an adaptive platform trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>S. aureus<\/jats:italic>\n                      Network Adaptive Platform (SNAP) trial [\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05137119\">NCT05137119<\/jats:ext-link>\n                      ] is a pragmatic, randomised, multicentre adaptive platform trial that compares different SAB therapies for 90-day mortality rates. For this intervention (\u2018Dabi-SNAP\u2019), patients receiving therapy with an oral FXaI will be randomised to continue as usual or to change to dabigatran as of the next scheduled dose. All subjects will receive standard of care antibiotics and\/or antibiotics allocated through other active domains in the platform. As the choice of anticoagulant may not demonstrate large differences in mortality, a ranked composite of death and adverse outcomes (Desirability of Outcome Ranking, or DOOR) was chosen as the primary outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      The study is conditionally approved by the research ethics board of the McGill University Health Centre: identifier 2025-10900. Trial results will be published open access in a peer-reviewed journal and presented at a global infectious disease conference. The trial is registered at clinicaltrials.gov with the identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06650501\">NCT06650501<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT0665050\">NCT0665050<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107493","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T18:35:34Z","timestamp":1765564534000},"page":"e107493","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the\n                    <i>Staphylococcus aureus<\/i>\n                    Network Adaptive Platform (SNAP) randomised controlled trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05137119","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06650501","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct0665050","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0783-0624","authenticated-orcid":false,"given":"Emily G","family":"McDonald","sequence":"first","affiliation":[{"name":"Department of Medicine, McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Cheng","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S","family":"Davis","sequence":"additional","affiliation":[{"name":"The University of Newcastle School of Medicine and Public Health, Callaghan, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L","family":"Goodman","sequence":"additional","affiliation":[{"name":"Centre for Clinical Infection and Diagnostics Research, Guy's and Saint Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"King\u2019s College London Faculty of Life Sciences and Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R","family":"Lawler","sequence":"additional","affiliation":[{"name":"Department of Cardiology, McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Marsh","sequence":"additional","affiliation":[{"name":"The University of Western Australia - Perth Campus, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-1613","authenticated-orcid":false,"given":"Dominik","family":"Mertz","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Technion Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rodriguez-Ba\u00f1o","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M","family":"Siegal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-8356","authenticated-orcid":false,"given":"Steven YC","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Walls","sequence":"additional","affiliation":[{"name":"Middlemore Hosp, Middlemore, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-4239","authenticated-orcid":false,"given":"Todd C","family":"Lee","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026010703480110000_15.12.e107493.1","first-page":"2221","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","year":"2019","journal-title":"Lancet"},{"key":"2026010703480110000_15.12.e107493.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.03.015"},{"key":"2026010703480110000_15.12.e107493.3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/cid\/ciac177","article-title":"How Generalizable Are Randomized Controlled Trials (RCTs) in Staphylococcus aureus Bacteremia? A Description of the Mortality Gap Between RCTs and Observational Studies","volume":"75","author":"Bai","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026010703480110000_15.12.e107493.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac476"},{"key":"2026010703480110000_15.12.e107493.5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/cid\/ciae289","article-title":"Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial","volume":"79","author":"Anpalagan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026010703480110000_15.12.e107493.6","unstructured":"de Kretser D , Mora J , Bloomfield M , et al . Early oral antibiotic switch in Staphylococcus aureus bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis 2023.:ciad666."},{"key":"2026010703480110000_15.12.e107493.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105911"},{"key":"2026010703480110000_15.12.e107493.8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00408-023-00599-6","article-title":"The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies","volume":"201","author":"Pilia","year":"2023","journal-title":"Lung"},{"key":"2026010703480110000_15.12.e107493.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"2026010703480110000_15.12.e107493.10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00896-10"},{"key":"2026010703480110000_15.12.e107493.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04529.x"},{"key":"2026010703480110000_15.12.e107493.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215333","article-title":"Adjunctive dabigatran therapy improves outcome of experimental left-sided Staphylococcus aureus endocarditis","volume":"14","author":"Lerche","year":"2019","journal-title":"PLoS ONE"},{"key":"2026010703480110000_15.12.e107493.13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0038-1639586","article-title":"Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition","volume":"118","author":"Peetermans","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026010703480110000_15.12.e107493.14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/cid\/ciaa661","article-title":"Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study","volume":"73","author":"Butt","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026010703480110000_15.12.e107493.15","doi-asserted-by":"crossref","first-page":"033","DOI":"10.1093\/ofid\/ofad500.033","article-title":"978. Association of oral anticoagulation therapy with dabigatran and the incidence rate of Staphylococcus aureus bacteremia among patients with atrial fibrillation","volume":"10","author":"Hasegawa","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026010703480110000_15.12.e107493.16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001830"},{"key":"2026010703480110000_15.12.e107493.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.09.001"},{"key":"2026010703480110000_15.12.e107493.18","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2021-0120"},{"key":"2026010703480110000_15.12.e107493.19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026010703480110000_15.12.e107493.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530010049034"},{"key":"2026010703480110000_15.12.e107493.21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ495"},{"key":"2026010703480110000_15.12.e107493.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-023-07718-x","article-title":"A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial","volume":"24","author":"Mahar","year":"2023","journal-title":"Trials"},{"key":"2026010703480110000_15.12.e107493.23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6737","article-title":"Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia","volume":"13","author":"Sun","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026010703480110000_15.12.e107493.24","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02117-21","article-title":"Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study","volume":"66","author":"Caffrey","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:50:54Z","timestamp":1767786654000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-107493"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107493","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}